An autocrine Vitamin D-driven Th1 shutdown program can be exploited for COVID-19

Reuben McGregor, Daniel Chauss, Tilo Freiwald, Bingyu Yan, Luopin Wang, Estefanía Nova‐Lamperti, Zonghao Zhang, Heather Teague, Erin E. West, Jack Bibby, Audrey Kelly, Amna Malik, Alexandra F. Freeman, Daniella M. Schwartz, Didier Portilla, Susan John, Paul Lavender, Michail S. Lionakis, Nehal N. Mehta, Claudia Kemper, Nichola Cooper, Giovanna Lombardi, Arian Laurence, Majid Kazemian, Behdad AfzalibioRxiv 2020 · DOI

TL;DR

This paper reveals a novel autocrine mechanism where Vitamin D (VitD) orchestrates the shutdown of pro-inflammatory Th1 immune responses, a process that appears to be impaired in severe COVID-19. The findings suggest that VitD, in combination with other immunomodulatory drugs like corticosteroids, could be a promising therapeutic strategy to dampen the hyperinflammation seen in COVID-19.

What Problem Does This Paper Address?

Severe COVID-19 is characterized by a dangerous overreaction of the immune system, specifically hyperinflammation driven by excessive pro-inflammatory responses, particularly from Th1 cells. While the importance of shutting down these responses for tissue protection is known, the precise molecular mechanisms governing this shutdown remain poorly understood. This lack of understanding limits the development of effective therapies to control this damaging inflammation. The paper aims to elucidate these mechanisms and explore potential therapeutic interventions.

Methods

The researchers employed a multi-pronged approach:

  • Single-cell RNA sequencing (scRNA-seq): This was crucial for analyzing gene expression profiles in individual immune cells from both COVID-19 patients and healthy controls, allowing for detailed characterization of cell populations and their functional states.
  • Flow Cytometry: Used for cell sorting and to analyze cytokine production (e.g., IFN-γ, IL-10) by T cells under various experimental conditions.
  • CUT&RUN and ChIP-seq: These techniques were used to investigate the epigenetic landscape, specifically histone acetylation (H3K27Ac), and to map the binding sites of key transcription factors (like c-JUN and BACH2) on the genome.
  • Western Blotting: Employed to detect and quantify protein expression levels of key molecules.
  • Phospho-kinase Protein Array: Used to identify signaling pathways that are activated or inhibited by VitD treatment.
  • Functional Assays: Included STAT3 inhibition and knock-down experiments to determine the role of specific signaling molecules in VitD-induced responses.
  • In vivo studies: Confocal imaging of psoriatic skin samples was used to validate findings in a human disease context.

Datasets

The study utilized several datasets:

  • Bronchoalveolar Lavage Fluid (BALF) samples: From patients with COVID-19 and healthy controls (sourced from GSE145926 and GSE122960).
  • Peripheral Blood Mononuclear Cells (PBMCs): From COVID-19 patients and healthy controls (sourced from GSE150728).
  • Lung biopsy samples: From COVID-19 patients and healthy controls (sourced from GSE147507 and HRA000143).
  • Psoriasis patient skin biopsies: Used for in vivo validation.
  • Publicly available datasets: For Tr1 cell gene lists (GSE139990) and sorted mouse CD4+ T cell transcriptomes (GSE45975).

Key Insights and Ideas

  • Complement as a Trigger: The study identifies complement activation as an initial trigger that prompts T cells to express the Vitamin D Receptor (VDR) and the enzyme CYP27B1, which activates VitD. This sets up an autocrine loop where T cells can respond to VitD.
  • VitD's Shutdown Mechanism: VitD acts as a switch, transitioning pro-inflammatory IFN-γ+ Th1 cells into suppressive IL-10+ Th1 cells. This is a critical step in resolving inflammation and preventing tissue damage.
  • Epigenetic Remodeling: VitD induces significant changes in the epigenetic landscape of T cells, creating super-enhancers and recruiting key transcription factors like c-JUN and BACH2. These factors are crucial for orchestrating the shutdown program.
  • Impaired Shutdown in COVID-19: In patients with severe COVID-19, the expression of VitD-repressed genes is elevated, and the VitD-driven shutdown program appears to be significantly impaired, contributing to the persistent hyperinflammation.
  • VitD and Corticosteroids Synergy: The study highlights that VitD and corticosteroids (like dexamethasone) share overlapping mechanisms and that combining them could be a potent strategy to counteract the detrimental gene expression patterns seen in severe COVID-19.

Key Results

  • VitD Induces VDR and CYP27B1: Complement activation in T cells leads to the induction of VDR and CYP27B1, enabling autocrine VitD signaling.
  • VitD Reprograms T cells: VitD treatment in healthy T cells leads to the repression of pro-inflammatory genes (like IFNG, IL17A) and induction of anti-inflammatory genes (like IL10, IL6).
  • c-JUN and BACH2 are Key Regulators: VitD treatment induces the expression and activation of transcription factors c-JUN and BACH2, which are critical for mediating VitD's effects on gene expression and T cell function.
  • IL-6-STAT3 Axis: VitD induces IL-6, which in turn phosphorylates STAT3, a critical step in promoting IL-10 production and the Th1 shutdown.
  • COVID-19 T cells Show Impaired VitD Response: CD4+ T cells from COVID-19 patients show a de-repression of genes normally suppressed by VitD, indicating a failure in the VitD-driven shutdown program.
  • Therapeutic Prediction: Alfacalcidol (an active VitD metabolite) and corticosteroids were identified as top predicted drugs to counteract the gene expression patterns in COVID-19 T cells.
  • Strong Discriminatory Signatures: Th1 and VitD-repressed gene signatures were highly effective in distinguishing COVID-19 patient T cells from healthy controls, with AUC values of 0.91 and 0.80, respectively.

Limitations and Future Work

  • In vitro vs. In vivo: While the study provides strong mechanistic insights from in vitro experiments, further in vivo validation in relevant animal models and clinical trials is necessary to confirm the therapeutic efficacy of VitD-based strategies.
  • Monotherapy vs. Combination Therapy: The authors suggest that VitD is unlikely to be effective as a monotherapy and that combination therapy, particularly with corticosteroids, is more promising. Future work should focus on optimizing combination regimens.
  • Potential Pro-inflammatory Effects of IL-6: The paper acknowledges that while IL-6 induces IL-10 in T cells, it can have pro-inflammatory effects on other cell types. This potential concern could be mitigated by adjunct VitD therapy.
  • Mechanisms of Impairment in COVID-19: While the study shows the VitD shutdown program is impaired in COVID-19, further research could delve deeper into the specific molecular reasons for this impairment.
  • Broader Applications: The identified VitD-driven Th1 shutdown program could potentially be relevant for other inflammatory and autoimmune diseases where Th1 responses play a pathogenic role.

Summary updated

Abstract

Pro-inflammatory immune responses are necessary for effective pathogen clearance, but cause severe tissue damage if not shut down in a timely manner <sup>1,2</sup> . Excessive complement and IFN-γ-associated responses are known drivers of immunopathogenesis <sup>3</sup> and are among the most highly induced immune programs in hyper-inflammatory SARS-CoV2 lung infection <sup>4</sup> . The molecular mechanisms that govern orderly shutdown and retraction of these responses remain poorly understood. Here, we show that complement triggers contraction of IFN-γ producing CD4 <sup>+</sup> T helper (Th) 1 cell responses by inducing expression of the vitamin D (VitD) receptor (VDR) and CYP27B1, the enzyme that activates VitD, permitting T cells to both activate and respond to VitD. VitD then initiates the transition from pro-inflammatory IFN-γ <sup>+</sup> Th1 cells to suppressive IL-10 <sup>+</sup> Th1 cells. This process is primed by dynamic changes in the epigenetic landscape of CD4 <sup>+</sup> T cells, generating superenhancers and recruiting c-JUN and BACH2, a key immunoregulatory transcription factor <sup>5-7</sup> . Accordingly, cells in psoriatic skin treated with VitD increased BACH2 expression, and BACH2 haplo-insufficient CD4 <sup>+</sup> T cells were defective in IL-10 production. As proof-of-concept, we show that CD4 <sup>+</sup> T cells in the bronchoalveolar lavage fluid (BALF) of patients with COVID-19 are Th1-skewed and that VDR is among the top regulators of genes induced by SARS-CoV2. Importantly, genes normally down-regulated by VitD were de-repressed in CD4 <sup>+</sup> BALF T cells of COVID-19, indicating that the VitD-driven shutdown program is impaired in this setting. The active metabolite of VitD, alfacalcidol, and cortico-steroids were among the top predicted pharmaceuticals that could normalize SARS-CoV2 induced genes. These data indicate that adjunct therapy with VitD in the context of other immunomodulatory drugs may be a beneficial strategy to dampen hyperinflammation in severe COVID-19.
BibTeX
@misc{mcgregor2020autocrine,
  author = {Reuben McGregor and Daniel Chauss and Tilo Freiwald and Bingyu Yan and Luopin Wang and Estefanía Nova‐Lamperti and Zonghao Zhang and Heather Teague and Erin E. West and Jack Bibby and Audrey Kelly and Amna Malik and Alexandra F. Freeman and Daniella M. Schwartz and Didier Portilla and Susan John and Paul Lavender and Michail S. Lionakis and Nehal N. Mehta and Claudia Kemper and Nichola Cooper and Giovanna Lombardi and Arian Laurence and Majid Kazemian and Behdad Afzali},
  title = {{An autocrine Vitamin D-driven Th1 shutdown program can be exploited for COVID-19}},
  year = {2020},
  doi = {10.1101/2020.07.18.210161},
  howpublished = {bioRxiv},
}
Figure